Krystal Biotech, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Krystal Biotech, Inc. (KRYS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 323.08 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-03
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 47.58K shares, a 40.50% decline year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 275.50K shares, a 7.71% increase year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 10.50K shares, a 79.59% decline year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 49.66K shares, a 29.08% decline year-over-year.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 395.90K shares, a 13.56% increase from fiscal 2024.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 348.64K shares, a 19.90% decline from fiscal 2023.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 435.28K shares, a 79.57% decline from fiscal 2022.
- Krystal Biotech, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.13M shares, a 49.78% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | 47.58K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | 323.08K shares 10-Q · filed 2026-08-03 | 333.58K shares derived: sum of 3 quarters · filed 2026-08-03 | 383.24K shares derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2026-03-31 | 275.50K shares 10-Q · filed 2026-05-04 | 286.00K shares derived: sum of 2 quarters · filed 2026-05-04 | 335.66K shares derived: sum of 3 quarters · filed 2026-05-04 | 415.63K shares derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-12-31 | 10.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | 60.16K shares derived: sum of 2 quarters · filed 2026-02-17 | 140.13K shares derived: sum of 3 quarters · filed 2026-08-03 | 395.90K shares 10-K · filed 2026-02-17 | ||
| 2025-09-30 | 49.66K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | 129.63K shares derived: sum of 2 quarters · filed 2026-08-03 | 385.40K shares 10-Q · filed 2025-11-03 | 436.84K shares derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-06-30 | 79.97K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | 335.74K shares 10-Q · filed 2026-08-03 | 387.18K shares derived: sum of 3 quarters · filed 2026-08-03 | 457.20K shares derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-03-31 | 255.77K shares 10-Q · filed 2026-05-04 | 307.21K shares derived: sum of 2 quarters · filed 2026-05-04 | 377.23K shares derived: sum of 3 quarters · filed 2026-05-04 | 477.67K shares derived: sum of 4 quarters · filed 2026-05-04 | ||
| 2024-12-31 | 51.44K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | 121.46K shares derived: sum of 2 quarters · filed 2026-02-17 | 221.90K shares derived: sum of 3 quarters · filed 2026-02-17 | 348.64K shares 10-K · filed 2026-02-17 | ||
| 2024-09-30 | 70.02K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | 170.46K shares derived: sum of 2 quarters · filed 2025-11-03 | 297.20K shares 10-Q · filed 2025-11-03 | 312.70K shares derived: sum of 4 quarters · filed 2025-11-03 | ||
| 2024-06-30 | 100.44K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | 227.18K shares 10-Q · filed 2025-08-04 | 242.68K shares derived: sum of 3 quarters · filed 2025-08-04 | 273.18K shares derived: sum of 4 quarters · filed 2025-08-04 | ||
| 2024-03-31 | 126.74K shares 10-Q · filed 2025-05-06 | 142.24K shares derived: sum of 2 quarters · filed 2025-05-06 | 172.74K shares derived: sum of 3 quarters · filed 2025-05-06 | 274.42K shares derived: sum of 4 quarters · filed 2025-05-06 | ||
| 2023-12-31 | 15.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | 46.00K shares derived: sum of 2 quarters · filed 2025-02-19 | 147.68K shares derived: sum of 3 quarters · filed 2025-02-19 | 435.28K shares 10-K · filed 2025-02-19 | ||
| 2023-09-30 | 30.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | 132.18K shares derived: sum of 2 quarters · filed 2024-11-04 | 419.78K shares 10-Q · filed 2024-11-04 | 592.28K shares derived: sum of 4 quarters · filed 2024-11-04 | ||
| 2023-06-30 | 101.68K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | 389.28K shares 10-Q · filed 2024-08-05 | 561.78K shares derived: sum of 3 quarters · filed 2024-08-05 | 750.78K shares derived: sum of 4 quarters · filed 2024-08-05 | ||
| 2023-03-31 | 287.60K shares 10-Q · filed 2024-05-06 | 460.10K shares derived: sum of 2 quarters · filed 2024-05-06 | 649.10K shares derived: sum of 3 quarters · filed 2024-05-06 | 1.24M shares derived: sum of 4 quarters · filed 2024-05-06 | ||
| 2022-12-31 | 172.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | 361.50K shares derived: sum of 2 quarters · filed 2024-02-26 | 951.00K shares derived: sum of 3 quarters · filed 2024-02-26 | 2.13M shares 10-K · filed 2024-02-26 | ||
| 2022-09-30 | 189.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | 778.50K shares derived: sum of 2 quarters · filed 2022-11-07 | 1.96M shares 10-Q · filed 2022-11-07 | 2.21M shares derived: sum of 4 quarters · filed 2023-02-27 | ||
| 2022-06-30 | 589.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 1.77M shares 10-Q · filed 2022-08-08 | 2.02M shares derived: sum of 3 quarters · filed 2023-02-27 | 2.39M shares derived: sum of 4 quarters · filed 2023-02-27 | ||
| 2022-03-31 | 1.18M shares 10-Q · filed 2022-05-09 | 1.43M shares derived: sum of 2 quarters · filed 2023-02-27 | 1.80M shares derived: sum of 3 quarters · filed 2023-02-27 | 2.10M shares derived: sum of 4 quarters · filed 2023-02-27 | ||
| 2021-12-31 | 250.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | 622.50K shares derived: sum of 2 quarters · filed 2023-02-27 | 920.00K shares derived: sum of 3 quarters · filed 2023-02-27 | 1.42M shares 10-K · filed 2023-02-27 | ||
| 2021-09-30 | 372.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | 670.00K shares derived: sum of 2 quarters · filed 2021-11-08 | 1.17M shares 10-Q · filed 2021-11-08 | 1.32M shares derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2021-06-30 | 297.50K shares 10-Q · filed 2021-08-09 | 799.95K shares 10-Q · filed 2021-08-09 | 950.95K shares derived: sum of 3 quarters · filed 2022-02-28 | 1.15M shares derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2021-03-31 | 502.45K shares 10-Q · filed 2021-05-10 | 653.45K shares derived: sum of 2 quarters · filed 2022-02-28 | 849.30K shares derived: sum of 3 quarters · filed 2022-02-28 | 1.16M shares derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-12-31 | 151.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | 346.85K shares derived: sum of 2 quarters · filed 2022-02-28 | 662.25K shares derived: sum of 3 quarters · filed 2022-02-28 | 891.25K shares 10-K · filed 2022-02-28 | ||
| 2020-09-30 | 195.85K shares 10-Q · filed 2021-11-08 | 511.25K shares derived: sum of 2 quarters · filed 2021-11-08 | 740.25K shares 10-Q · filed 2021-11-08 | 760.75K shares derived: sum of 4 quarters · filed 2021-11-08 | ||
| 2020-06-30 | 315.40K shares 10-Q · filed 2021-08-09 | 544.40K shares 10-Q · filed 2021-08-09 | 564.90K shares derived: sum of 3 quarters · filed 2021-08-09 | 594.40K shares derived: sum of 4 quarters · filed 2021-08-09 | ||
| 2020-03-31 | 229.00K shares 10-Q · filed 2021-05-10 | 249.50K shares derived: sum of 2 quarters · filed 2021-05-10 | 279.00K shares derived: sum of 3 quarters · filed 2021-05-10 | 321.00K shares derived: sum of 4 quarters · filed 2021-05-10 | ||
| 2019-12-31 | 20.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | 50.00K shares derived: sum of 2 quarters · filed 2021-03-01 | 92.00K shares derived: sum of 3 quarters · filed 2021-03-01 | 159.50K shares 10-K · filed 2021-03-01 | ||
| 2019-09-30 | 29.50K shares 10-Q · filed 2020-11-09 | 71.50K shares derived: sum of 2 quarters · filed 2020-11-09 | 139.00K shares 10-Q · filed 2020-11-09 | 160.50K shares derived: sum of 4 quarters · filed 2020-11-09 | ||
| 2019-06-30 | 42.00K shares 10-Q · filed 2020-08-07 | 109.50K shares 10-Q · filed 2020-08-07 | 131.00K shares derived: sum of 3 quarters · filed 2020-08-07 | 169.50K shares derived: sum of 4 quarters · filed 2020-08-07 | ||
| 2019-03-31 | 67.50K shares 10-Q · filed 2020-05-04 | 89.00K shares derived: sum of 2 quarters · filed 2020-05-04 | 127.50K shares derived: sum of 3 quarters · filed 2020-05-04 | 208.00K shares derived: sum of 4 quarters · filed 2020-05-04 | ||
| 2018-12-31 | 21.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | 60.00K shares derived: sum of 2 quarters · filed 2020-03-10 | 140.50K shares derived: sum of 3 quarters · filed 2020-03-10 | 195.50K shares 10-K · filed 2020-03-10 | ||
| 2018-09-30 | 38.50K shares 10-Q · filed 2019-11-04 | 119.00K shares derived: sum of 2 quarters · filed 2019-11-04 | 174.00K shares 10-Q · filed 2019-11-04 | 238.90K shares derived: sum of 4 quarters · filed 2019-11-04 | ||
| 2018-06-30 | 80.50K shares 10-Q · filed 2019-08-05 | 135.50K shares 10-Q · filed 2019-08-05 | 200.40K shares derived: sum of 3 quarters · filed 2019-08-05 | 207.15K shares derived: sum of 4 quarters · filed 2019-08-05 | ||
| 2018-03-31 | 55.00K shares 10-Q · filed 2019-05-07 | 119.90K shares derived: sum of 2 quarters · filed 2019-05-07 | 126.65K shares derived: sum of 3 quarters · filed 2019-05-07 | 172.60K shares derived: sum of 4 quarters · filed 2019-05-07 | ||
| 2017-12-31 | 64.90K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | 71.65K shares derived: sum of 2 quarters · filed 2018-11-05 | 117.60K shares derived: sum of 3 quarters · filed 2018-11-05 | 71.65K shares 10-K · filed 2018-03-12 | ||
| 2017-09-30 | 6.75K shares 10-Q · filed 2018-11-05 | 52.70K shares derived: sum of 2 quarters · filed 2018-11-05 | 6.75K shares 10-Q · filed 2018-11-05 | 71.65M shares 10-Q · filed 2017-11-13 | ||
| 2017-06-30 | 45.95K shares 10-Q · filed 2018-08-06 | 45.95K shares 10-Q · filed 2018-08-06 | ||||
| 2017-03-31 | 0.00 shares 10-Q · filed 2018-05-07 | |||||
| 2016-12-31 | 142.10K shares 10-K · filed 2018-03-12 | 142.10M shares 10-Q · filed 2017-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |